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Abstract. The accuracy of 3DVH (Sun Nuclear Corporation, USA) reported DVH metrics for 
target volumes and Organs at Risk (OARs) for two Prostate Volumetric Modulated Arc 
Therapy (VMAT) plans was studied. The accuracy of 3DVH estimated DVH metrics in the 
presence of Multi Leaf Collimator (MLC) systematic errors was also tested with error 
introduced plans calculated in Pinnacle. The results of the study show that the DVH metrics 
estimated by 3DVH for error-free plans agree with the TPS calculation within 3%. The D95 to 
PTV was shown to be sensitive in detecting studied MLC errors. However the accuracy of 
3DVH estimated DVH metrics for Target Volumes and OARs in the presence of MLC errors 
for VMAT prostate plans has limitations with this small data set. Although for most situations 
values matched within 3% for small MLC errors, there was up to a 9.8% difference between 
the TPS and 3DVH in the presence of a simulated 5mm MLC positioning error. Further study 
with more plans including other treatment sites is required to fully assess the performance of 
3DVH in detecting potential clinical delivery errors. 
1.  Introduction 
Measurement based three dimensional (3D) dosimetric verification is highly recommended to ensure 
dose calculation and delivery accuracy of complex modern radiotherapy techniques [1, 2]. Recently 
many dosimetric systems have been introduced that provide semi 3D or 3D dose information of the 
delivered treatment plan in a specific phantom geometry. Many metrics have been recommended to 
evaluate the agreement between measured and calculated dose matrices quantitatively [3]. Among 
them gamma (γ) index is widely implemented in many dosimetric systems and used in clinics [4]. 
However due to lack of correlation between these quantitative metrics and clinically relevant dose 
parameters there is an increasing demand to evaluate delivered dose to the relevant clinical structures 
in the patient geometry. Different approaches have been adapted by different dosimetric systems to 
estimate the dose in patient geometry based on the measurement performed by detectors [5, 6]. Sun 
Nuclear Corporation, USA recently introduced a patient dosimetric QA software system, 3DVH, that 
estimates the dose to clinical structures in patient geometry using a planned dose perturbation (PDP) 
algorithm. In this study we evaluate the accuracy of 3DVH software in estimating dose to patient 
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geometry for Volumetric Modulated Arc Therapy (VMAT) for prostate cancer. To investigate a 
situation where there may be a delivery error, the accuracy of the software in estimating the dose in 
the presence of systematic errors in Multi Leaf Collimator (MLC) position has been studied. 
2.  Materials and Methods 
2.1.  Planning and delivery system 
A 6MV photon beam model for an Elekta –Synergy (Elekta Ltd, Crawley, UK) linac in the Pinnacle 
(Philips Ltd, USA) treatment planning system (TPS), v9.2, was used to generate all the treatment plans 
in this study. The Elekta–Synergy linac used has the MLCi head and the VMAT plans were delivered 
using continuously variable dose rate (CVDR) with Integrity, v1.1, console software. 
2.2.  Clinical plans and simulated errors 
Two prostate VMAT plans were considered to study the accuracy of 3DVH in estimating the delivered 
dose to patient geometry. Systematic shifts in MLC leaf position, ranging from ±1mm to ±5mm in 
steps of 1mm, were introduced to the VMAT arc using in-house software [6]. The plans with MLC 
error were calculated in Pinnacle to study the impact of error on target volume and OAR doses. 
2.3.  ArcCHECK measurement and verification 
The error-free and error-introduced plans were measured using the ArcCHECK dosimetric system. A 
point dose measurement using a CC13 ion chamber was also performed at the centre of the 
ArcCHECK phantom for all plans to provide the measured point dose information to the 3DVH, v3.0, 
software. The PDP algorithm implemented in 3DVH perturbs the planned patient dose voxels based 
on the ray traced error maps obtained from ArcCHECK measurements and TPS dose matrix calculated 
in ArcCHECK geometry. More details on the description of the algorithm can be found elsewhere [7].  
2.4.  Comparison metrics 
The TPS and 3DVH estimated DVH parameters including D95 to CTV and PTV and mean dose to 
PTV, CTV, Rectum and Bladder were compared to verify the dosimetric accuracy of delivered error-
free plans. A minimum 3% agreement between the TPS and 3DVH estimated DVH metrics for error 
free plans are expected to accept the plan.  To assess the accuracy of 3DVH reported DVH metrics in 
the presence of simulated errors, the errors were introduced to the patient plan in the TPS using in-
house software and dose calculations were performed. The TPS calculated DVH metrics for the error 
plans were compared against the 3DVH reported metrics for error introduced plans. 
The dose matrices calculated by the TPS and estimated by 3DVH were compared using γ analysis 
and Dose Volume Histogram (DVH) metrics of the clinical structures. The γ analysis was performed 
using 2%/2mm and 3%/3mm criteria using global (G) and local (L) dose tolerances. The dose 
elements within the ArcCHECK-PDP (ACPDP) calculation volume and high dose threshold of 10% of 
the maximum dose were used in the γ analysis. The change in γ pass rate with increased magnitude of 
errors was studied to assess the sensitivity of the 3DVH estimated dose matrix in identifying delivery 
errors. 
3.  Results  
3.1.  Gamma comparison 
Figure1 shows the γ pass rate results of the 3DVH predicted dose matrix and TPS calculated dose 
matrix for error-free and error introduced plans with various tolerance criteria. In general Case 1 
showed less variation in γ pass rate at all tolerance levels for introduced errors. The pass rate for Case 
2 varied as a function of introduced error. 3%/3mm global criteria (3%G/3mm) was observed to be  
less sensitive in predicting errors. 2%G/2mm and 3%L/3mm tolerance criteria showed similar pass 
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rate variations for all plans. 2%L/2mm criteria showed high sensitivity to error for Case 2, the pass 
rate was reduced from 96.3%, for the error-free plan, to 83.2% for the plan with 5mm error (figure1).  
 
 
Figure 1. γ pass rate values for γ comparison between error free and +ve and –ve MLC error introduced plans 
for the studied cases with different γ tolerance criteria.            
3.2.  Change in DVH metrics calculated by TPS 
Figure 2 shows the percentage change in DVH metrics between error-free and +ve MLC error 
introduced plans calculated by the TPS. Figure 3 shows similar data for –ve MLC shift plans. As 
expected, the D95 of PTV decreased as the MLC error value increases. A maximum change of -9.8% 
was observed for the PTV of case2 for the plan with -5mm MLC error. For CTV the D95 decreased 
for both +ve and –ve errors for case1. For case 2 the D95 improved with +ve errors and decreased with 
–ve errors. A maximum change of -4.6% decrease in D95 was observed for the CTV with -5mm error. 
The mean dose to PTV was decreased bya maximum -3.7% with -5mm error. The mean dose to 
Bladder was increased with +ve MLC error and decreased with –ve MLC errors for both cases. A 
maximum change of -6.9% was observed for case 1 with -5mm error. The mean rectum dose showed 
minimum change for both cases with +ve MLC errors whereas with –ve errors the mean dose 
increased in both cases and case 2 showed an increase of 6.2% with -5mm MLC error. 
 
Figure 2. Percentage (%) difference in considered DVH metrics for target volumes and OARs for error-free (EF) 
and +ve MLC error introduced plans by TPS and 3DVH. 
 
 
Figure 3. Percentage (%) difference in considered DVH metrics for target volumes and OARs for error-free (EF) 
and -ve MLC error introduced plans by TPS and 3DVH. 
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3.3.  Accuracy of 3DVH estimated DVH metrics 
The DVH metrics estimated by 3DVH for error-free and +ve and –ve MLC error introduced plans are 
shown in figures 2 and 3. The D95 and mean dose of error-free plans estimated by 3DVH for clinical 
structures agreed with the TPS within 3%. For MLC error introduced plans the % difference of PTV 
D95 estimated by 3DVH was consistently less compared to the TPS. A maximum difference of -9.4% 
was observed between the 3DVH estimated and TPS calculated D95 values for PTV for a plan with 
5mm MLC error (figure2). The TPS calculated D95 to CTV showed only small magnitude variation 
for MLC errors for both cases. The 3DVH estimated D95 values followed the same trend as TPS 
calculated values (figures2 and 3). The mean dose to target volumes showed only small changes due to 
+ve MLC errors for studied cases. 3DVH estimation also followed the same trend. In the case of –ve 
MLC errors for case 2 the 3DVH estimated mean dose change was consistently higher compared to 
TPS calculated changes. A maximum difference of 4.5% was observed between TPS and 3DVH mean 
dose values at -5 mm MLC error. The % difference in mean dose to OARs, estimated by 3DVH, 
showed inconsistent results compared to TPS calculation. The % difference in bladder dose calculated 
by TPS for Case 1 and the dose to rectum and bladder estimated by 3DVH showed contrary results 
compared to TPS calculations. For +ve MLC errors the TPS calculated mean dose to Rectum  showed 
minor changes (maximum -1.4% for 5mm error for case 1).The 3DVH estimated % differences for 
Case 2 were observed to have  consistently higher values compared to TPS calculations. In the case of 
–ve MLC errors the 3DVH estimated % difference was consistently low compared to TPS calculation 
for Case 2. The % difference in mean dose to bladder for Case 1 estimated by 3DVH showed an 
inverse trend to that with TPS calculation. The 3DVH and TPS calculated mean dose for Rectum in 
Case 2 showed relatively close agreement, with a maximum difference of 3% observed between TPS 
calculated and 3DVH estimated mean dose for the plan with -4 mm error. 
4.  Discussion 
The DVH metrics estimated by 3DVH for error-free plans agreed with the TPS calculation within a 
generally accepted tolerance of 3%. Clinically significant changes (>5%) in D95 to PTV and mean 
dose to OARs were observed with the simulated MLC errors. 3DVH estimated D95% difference for 
error simulated plans agreed with TPS calculation only for –ve MLC error plan scenario of Case 2 
(figures 2 and 3). The mean dose to Rectum estimated by 3DVH in the presence of MLC error did not 
agree with the TPS calculation for Case2. Similarly the mean dose to Bladder estimated by 3DVH in 
the presence of MLC error did not agree with the TPS calculation for Case 1.The ACPDP has been 
shown to have limitations in predicting changes in DVH metrics due to the studied MLC shifts. 
However the γ pass rate with 2%L/2mm tolerance criteria showed a consistent decrease in pass rates 
with MLC error for at least one of the studied cases (Case 2 results in figure 1).    
5.  Conclusion 
The accuracy of 3DVH estimated DVH metrics for target volumes and OARs in MLC error 
introduced VMAT prostate plans has been shown to have limitations in this small data set with up to a 
9.8% difference between the TPS and 3DVH in the presence of a simulated 5mm MLC positioning 
error. Further study with more plans, including other treatment sites, is required to fully assess the 
performance of 3DVH in detecting potential clinical delivery errors. 
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